American Capital Advisory’s ResMed RMD Stock Holding History

American Capital Advisory’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12K	Buy	5 +1	+25%	+$249	﹤0.01%	660
2025 Q4	$964	Buy	4 +1	+33%	+$256	﹤0.01%	608
2025 Q3	$822	Buy	3 +1	+50%	+$273	﹤0.01%	579
2025 Q2	$516	Hold	2	–	–	﹤0.01%	623
2025 Q1	$448	Buy	+2	New	+$467	﹤0.01%	533

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

American Capital Advisory's RMD Position: Q1 2026 in Review

American Capital Advisory increased its ResMed (RMD) stake by 25% in Q1 2026, buying an estimated $249 and bringing the position to 5 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #660.

American Capital Advisory first reported a position in RMD in Q1 2025 and has held it in 5 quarters since. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

American Capital Advisory held 5 shares of ResMed worth $1.12K as of Q1 2026.
American Capital Advisory bought 1 ResMed share in Q1 2026, an estimated $249.
ResMed made up ﹤0.01% of American Capital Advisory's portfolio in Q1 2026, its #660 holding.
American Capital Advisory first reported a position in ResMed in Q1 2025 and has held it in 5 quarters since.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on American Capital Advisory's 13F filing for Q1 2026, filed 29 Apr 2026.